CytoSen Therapeutics
↗Orlando (Winter Springs), Florida, USA
CytoSen Therapeutics is a biopharmaceutical company that developed a proprietary natural killer (NK)-cell platform for cancer immunotherapy. The company pioneered particle-based NK cell expansion and activation technology, enabling the generation of large quantities of highly-active NK cells with enhanced cytotoxicity for cancer treatment. CytoSen's innovative nanoparticle processing technology was based on an exclusive license from the University of Central Florida (UCF) and further developed in collaboration with Nationwide Children's Hospital (NCH). The company focused on advancing NK-cell therapy for hematologic and solid tumors, with its lead program (CSTD002-NK) demonstrating exceptional clinical proof-of-concept data showing 8% relapse rates compared to 45% in matched controls.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology biotech, Cell therapy, Immunotherapy
SIZE & FINANCIALS
Employees:51-200
Founded:2014
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Private (acquired pre-IPO)
Total Raised:$0.8M-$6M
Investors:University of Central Florida Business Incubator, Kiadis Pharma N.V. (acquirer)
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Natural Killer (NK) Cell Therapy, Cell Expansion, Nanoparticle-enhanced immunotherapy, Ex vivo cell expansion
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Sanofi (via Kiadis Pharma acquisition in 2020)
Acquired By:Kiadis Pharma N.V. (later acquired by Sanofi in 2020) (2019-06-06)
Key Partnerships:University of Central Florida (UCF): Exclusive technology license for nanoparticle NK cell expansion platform, Nationwide Children's Hospital (NCH): Technology development and clinical collaboration, MD Anderson Cancer Center: Clinical proof-of-concept studies for CSTD002-NK (25-patient study), KBI Biopharma: Strategic manufacturing partnership for NK cells and nanoparticles (2018), University of Tennessee Research Foundation: Licensing agreement
COMPETITION
Position:Niche Player (acquired)
Competitors:Fate Therapeutics (NK cell programs), Glycostem Therapeutics (off-the-shelf NK cells), Celularity (NK cell therapy), Compass Therapeutics (cell-based immunotherapy), Other CAR-T and cell therapy companies in immuno-oncology space
LEADERSHIP
Key Executives:
Dean A. Lee, M.D. - Medical Director, Vice President, Co-founder
Robert Igarashi, Ph.D. - Co-founder
Trent Carrier, M.B.A., Ph.D. - Executive Management
Joseph S. Shan - Head of Clinical and Regulatory Affairs
Scientific Founders:Alicja Copik, Ph.D., Dean A. Lee, M.D., Robert Igarashi, Ph.D.
LINKS
Website:cytosen.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CytoSen Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.